Seeking Alpha

Investors lose patience with Trovagene

  • Shares of thinly traded nano cap Trovagene (TROV -8.8%) continue their slide today on 4x higher volume. Prices have now cratered 66% from the $10.27 August 5 high.
  • The company reported Q1 results earlier in the week. Notable by their absence are any revenues from its much-ballyhooed transrenal nucleic acid tests. It launched a BRAF test in its CLIA lab in October of last year and a KRAS test in March, but no revenues have been generated yet. Per its 10-Q, all of its $111K in revenues come from NPM1 royalties.
Comments (6)
  • 1880gh
    , contributor
    Comments (50) | Send Message
    whats going on help mike h
    16 May, 05:30 PM Reply Like
  • motie10
    , contributor
    Comment (1) | Send Message
    Was any explanation for the lack of revenues offered during the conference call? The KRAS test is probably too new, but the BRAF test has been available for 6 months.
    16 May, 05:50 PM Reply Like
  • jake319
    , contributor
    Comments (87) | Send Message
    Mmmmm Could this be another pump and dump?
    16 May, 08:11 PM Reply Like
  • ceristeare
    , contributor
    Comments (183) | Send Message
    Someone bought this stock at 10 bucks?? Way too early, I like it here and on the way down
    16 May, 09:54 PM Reply Like
  • GetOffMyLawn
    , contributor
    Comments (16) | Send Message
    ...and their likewise ballyhooed HPV test, launched OVER a YEAR ago, generated precisely ZERO $. Not only was it scrubbed from website but those foreign collaborations were erased. 10Q sez Perkin Elmer also terminated agreement. Seems they cant beat a pair of twos.
    18 May, 08:01 PM Reply Like
  • ceristeare
    , contributor
    Comments (183) | Send Message
    They are building a portfolio of scalable products, collecting patents, value, etc. Marketing products? We'll see.
    18 May, 11:04 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector